Navigation Links
Biopure's Stock Symbol Reverts to BPUR

CAMBRIDGE, Mass., Oct. 31 /PRNewswire-FirstCall/ -- Biopure Corporation (Nasdaq: BPUR) announced today that the trading symbol for its Class A common stock will revert from BPURD to BPUR at the open of the market on Wednesday, October 31, 2007. Outstanding warrants that trade on the OTCBB will revert to the following ticker symbols: BPREW reverting to BPURW; BPREZ reverting to BPURZ; and BPREL reverting to BPURL.

Biopure Corporation

Biopure Corporation develops, manufactures and markets pharmaceuticals, called oxygen therapeutics, that are intravenously administered to deliver oxygen to the body's tissues. Hemopure(R) [hemoglobin glutamer - 250 (bovine)], or HBOC-201, is approved for sale in South Africa for the treatment of surgical patients who are acutely anemic. Biopure has applied in the United Kingdom for regulatory approval of a proposed orthopedic surgical anemia indication. The company is developing Hemopure for several other indications and is supporting the U.S. Navy's government-funded efforts to develop a potential out-of-hospital trauma indication. Biopure's veterinary product Oxyglobin(R) [hemoglobin glutamer - 200 bovine)], or HBOC-301, the only oxygen therapeutic approved by both the U.S. Food and Drug Administration and the European Commission, is indicated for the treatment of anemia in dogs. Biopure has sold approximately 186,000 units of Oxyglobin, which have been used to treat an estimated 100,000 animals.

Statements in this release that are not strictly historical are forward- looking statements, including those statements implying that any planned clinical trial will be carried out or that study results will be as desired, statements related to the timing and response of the MHRA review and any statements that might imply that Hemopure may receive marketing approval in additional jurisdictions or for additional indications. Actual results and their timing may differ materially from those projected in these forward- looking statements due to risks and uncertainties. These risks include, without limitation, uncertainties regarding the company's financial position, including its limited cash resources and need to raise additional capital to pursue these initiatives, unexpected costs and expenses, delays and adverse determinations by regulatory authorities, unanticipated problems with the product's commercial use, whether or not product related, and with product distributors, sales agents or other third parties, delays in or unpredictable outcomes of clinical trials, and the other factors identified under the heading "Risk Factors" in the company's quarterly report on Form 10-Q filed on September 14, 2007, which can be accessed in the EDGAR database at the U.S. Securities and Exchange Commission's (SEC) website, The company undertakes no obligation to release publicly the results of any revisions to these forward-looking statements to reflect events or circumstances arising after the date hereof. A full discussion of the company's operations and financial condition can be found in the company's filings with the SEC.

The content of this release does not necessarily reflect the position or the policy of the U.S. Government or the Department of Defense, and no official endorsement should be inferred.

Contact: Tiana Gorham Herb Lanzet (Investors)

Biopure Corporation H.L. Lanzet Inc.

(617) 234-6826 (212) 888-4570

SOURCE Biopure Corporation
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Stockings Effective In Reducing The Effects Of Deep Vein Thrombosis
2. Risk of deep vein thrombosis less in people who were flight stockings when flying
3. Health and Human Services stockpiles 20 million bird flu Vaccines
4. Rich countries stock piling anti flu drugs with no stocks available for poor countries
5. Australian Government To Stockpile Anti-Bird Flu Drug Relenza
6. Bird Flu Threat Prompts Stockpiling Of Food And Medicine In America
7. Wake Up Call: U.N Takes Stock to Curb Fake Medicines Racket
8. Bird flu: the threat causes lowering in poultry stocks
9. OpenMED Nominated For Stockholm Challenge 2006 Award
10. Travel-Related Blood Clots Can Be Reduced By Using Flight Stockings
11. Time is ripe to take stock of depression
Post Your Comments:
(Date:10/13/2015)... ... 13, 2015 , ... The added calories and sugar in an average trick-or-treat ... a parent to do? Registered dietitians from Retrofit , the leading corporate weight ... year. , “Halloween is a high-calorie holiday,” said Dara Aronow, Registered Dietitian, Retrofit. ...
(Date:10/13/2015)... ... 2015 , ... Vision Group Holdings, the largest LASIK provider in North America, ... The LASIK Vision Institute and TLC Laser Eye Centers, Vision Group Holdings has performed ... correction. , Global Laser Vision will continue to operate in San Diego as it ...
(Date:10/13/2015)... ... October 13, 2015 , ... ... the United States, today announced the release of its limited edition holiday seasonal ... Cocktail Agua Fresca. All feature the unique flavor combinations and delicious taste Califia ...
(Date:10/13/2015)... ... 13, 2015 , ... ProText Kinetic Panel is a typography creation tool made ... can create energetic text animations in any layout without the use of keyframes. Using ... timeline and stylize the text. With intuitive on-screen controls, users can re-position and scale ...
(Date:10/13/2015)... Williamsport, PA (PRWEB) , ... October 13, 2015 , ... ... (SH) 2015 utility costs were 36 percent lower per square foot than in 2009. ... the actual cost of heating and cooling has decreased by eight percent. , ...
Breaking Medicine News(10 mins):
(Date:10/13/2015)... , Oct. 13, 2015  The spine division ... leader in musculoskeletal healthcare, will showcase its portfolio of ... Spine Society (NASS) annual meeting, October 14-17, 2015, in ... also host two clinical events: "Supplemental MIS ... Presentation Wednesday, October 14 12:30 – 1 p.m. ...
(Date:10/13/2015)... N.J. , Oct. 13, 2015  ContraVir ... the "Company"), a biopharmaceutical company focused on the ... announced the closing of its previously announced underwritten ... stock and warrants to purchase up to 3,000,000 ... fixed combined price to the public of $3.00. ...
(Date:10/13/2015)... JOLLA, Calif. , Oct. 13, 2015  Human ... revolutionize the practice of medicine, announced today the launch ... clinical research project that has the potential to transform ... San Diego, CA , at HLI,s headquarters ... in 2016 in other US and International cities. ...
Breaking Medicine Technology: